Fulltext

The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice

Tye GJ 1 , Ioannou K 2 , Amofah E 2 , Quartey-Papafio R 2 , Westrop SJ 2 , Krishnamurthy P 2 Show all authors , Noble A 3 , Harrison PM 4 , Gaensler KM 5 , Barber LD 2 , Farzaneh F 2

Affiliations 

  • 1 Department of Haematological Medicine, King's College London, Rayne Institute, London, UK ; Institute for Research in Molecular Medicine, Universiti Sains Malaysia, George town, Malaysia
  • 2 Department of Haematological Medicine, King's College London, Rayne Institute, London, UK
  • 3 Medical Research Council and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, Guy's Hospital, London, UK
  • 4 Division of Transplant and Mucosal Cell Biology, King's College London, London, UK
  • 5 Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, USA
Immun Ageing, 2015;12:6.
PMID: 26157468 DOI: 10.1186/s12979-015-0033-0

Abstract

Ineffective induction of T cell mediated immunity in older individuals remains a persistent challenge for vaccine development. Thus, there is a need for more efficient and sophisticated adjuvants that will complement novel vaccine strategies for the elderly. To this end, we have investigated a previously optimized, combined molecular adjuvant, CASAC (Combined Adjuvant for Synergistic Activation of Cellular immunity), incorporating two complementary Toll-like receptor agonists, CpG and polyI:C, a class-II epitope, and interferon (IFN)-γ in aged mice.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications